| Identification | More | [Name]
Ginsenoside Re | [CAS]
52286-59-6 | [Synonyms]
GINSENOSIDE GINSENOSIDE-RE
GINSENOSIDE RE
chikusetsusaponinivc
ginsenosideb2
2-O-(6-deoxy-alpha-L-mannopyranosyl)-(3beta,6alpha,12beta)-20-(beta-D-glucopyranosyloxy)-3,12-dihydroxydammar-24-en-6-yl-beta-D-glucopyranoside
Ginsenoside Re std.
98%byHPLC/CH90650
Panaxoside
GINSENOSIDE RE WITH HPLC
GINSENOSIDE-RE (GINSENOSIDE B2)
glucopyranosyloxy)-3,12-dihydroxydammar-24-en-6-yl2-O-(6-deoxy-α-L-mannopyranosyl)-
β-D-Glucopyranoside,(3β,6α,12β)-20-(β-D-
[20-(β-D-Glucopyranosyloxy)-3β,12β-dihydroxy-5α-dammar-24-en-6α-yl]2-O-(6-deoxy-α-L-mannopyranosyl)-β-D-glucopyranoside
[20-(β-D-Glucopyranosyloxy)-3β,12β-dihydroxydammar-24-en-6α-yl]2-O-(6-deoxy-α-L-mannopyranosyl)-β-D-glucopyranoside
20-(β-D-Glucopyranosyloxy)-3β,12β-dihydroxy-5α-dammar-24-en-6α-yl 2-O-(6-deoxy-α-L-mannopyranosyl)-β-D-glucopyranoside | [EINECS(EC#)]
257-814-6 | [Molecular Formula]
C48H82O18 | [MDL Number]
MFCD00133369 | [Molecular Weight]
947.15 | [MOL File]
52286-59-6.mol |
| Chemical Properties | Back Directory | [Melting point ]
201～203℃ | [Boiling point ]
1011.8±65.0 °C(Predicted) | [density ]
1.38±0.1 g/cm3(Predicted) | [storage temp. ]
2-8°C
| [solubility ]
DMSO (Slightly), Methanol (Slightly), Pyridine (Slightly) | [form ]
neat | [pka]
12.85±0.70(Predicted) | [color ]
White to Off-White | [InChIKey]
PWAOOJDMFUQOKB-WCZZMFLVSA-N | [LogP]
4.750 (est) | [CAS DataBase Reference]
52286-59-6(CAS DataBase Reference) |
| Safety Data | Back Directory | [Hazard Codes ]
Xn | [Risk Statements ]
R20/21/22:Harmful by inhalation, in contact with skin and if swallowed . | [Safety Statements ]
S26:In case of contact with eyes, rinse immediately with plenty of water and seek medical advice .
S36:Wear suitable protective clothing . | [WGK Germany ]
3
| [RTECS ]
LY9536700 | [HS Code ]
29389090 |
| Hazard Information | Back Directory | [Chemical Properties]
White solid | [Uses]
Ginsenoside Re is an extract from ginger, responsible for some of the pharmacological functions. It displays cardiac contractility, anti-ischemic and anti-arrythmic activities. | [Definition]
ChEBI: Ginsenoside Re is a ginsenoside found in Panax ginseng that is dammarane which is substituted by hydroxy groups at the 3beta, 6alpha, 12beta and 20 pro-S positions, in which the hydroxy groups at positions 6 and 20 have been converted to the corresponding alpha-L-rhamnopyranosyl-(1->2)-beta-D-glucopyranoside and beta-D-glucopyranoside respectively, and in which a double bond has been introduced at the 24-25 position. It has a role as a plant metabolite, an antioxidant, a neuroprotective agent, an anti-inflammatory agent, an antineoplastic agent and a nephroprotective agent. It is a 12beta-hydroxy steroid, a 3beta-hydroxy steroid, a beta-D-glucoside, a ginsenoside, a tetracyclic triterpenoid, a disaccharide derivative and a 3beta-hydroxy-4,4-dimethylsteroid. It derives from a hydride of a dammarane. | [in vivo]
Ginsenoside Re reduces insulin resistance in 3T3-L1 adipocytes and high-fat diet (HFD) rats through inhibition of JNK and NF-κB activation[2]. Intraperitoneal injection of lipopolysaccharide (LPS) at a dose of 20 mg/kg is lethal to mice, and 70% to 80% of the mice die within 60 h. However, pretreatment of the mice with Rg1 or Ginsenoside Re increases their survival rates in a dose-dependent manner. With the doses of Rg1 or Ginsenoside Re increase from 2.5 to 5 mg/kg, the survival rate is elevated from 60% to 90% (Rg1) or from 30% to 40% (Ginsenoside Re). All the mice administered Rg1 at a minimal dose of 10 mg/kg are protected from death compared to 80% survival of mice treated with an equal dose of Ginsenoside Re. To protect all the mice, 20 mg/kg Ginsenoside Re is needed. To investigate the anti-inflammatory potential of Rg1 and Ginsenoside Re, 1 mg/kg Rg1 or Ginsenoside Re is injected into rats and then challenged the animals with LPS. The injection procedure itself causes a transient stress-induced increase in body temperature of ~1.2°C in each group. Thereafter, LPS-challenged rats without pretreatment develope a robust biphasic fever, with the first peak reaching ~1.5°C at 2 h and the second peak reaching 1.8°C at 4 h. In contrast, the temperature changes for the Rg1-, Ginsenoside Re-, and TAK-242-treated groups are only 0.9, 1.2, and 0.8°C at 2 h and 1.3, 1.4, and 1.0°C at 4 h, respectively. Pretreatment with Rg1, Ginsenoside Re, or TAK-242 significantly attenuates LPS-induced alterations in body temperature[3]. | [target]
AMPK | TLR | p38MAPK | HO-1 | TNF-α | Potassium Channel | NO | Calcium Channel | ERK | Akt | mTOR | CD4 | Calcium Channel | c-Src | NOS | [IC 50]
Aβ1-40; Aβ1-42; NF-κB; JNK |
|
|